Last reviewed · How we verify
NCT04721210
The Effectiveness of Transcranial Magnetic Stimulation of Supplementary Motor Area (SMA) in Patients With Bladder Hypersensitivity and Bladder Pain
NA trial testing Transcranial magnetic stimulation in Bladder Hypersensitivity in 28 participants. Status unknown.
20 January 2022
Quick facts
| Lead sponsor | Joint-Stock Company North-West Center for Evidence-Based Medicine, Russian Federation |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | other |
| Enrollment | 28 |
| Start date | 20 January 2021 |
| Primary completion | 20 January 2022 |
| Estimated completion | 20 January 2022 |
| Sites | 1 location across Russia |
Drugs / interventions tested
- Transcranial magnetic stimulation — full drug profile →
Conditions studied
- Bladder Hypersensitivity — all drugs for Bladder Hypersensitivity →
Sponsor
Joint-Stock Company North-West Center for Evidence-Based Medicine, Russian Federation — full company profile →
Who can join
Adults 18 to 75, female only, with Bladder Hypersensitivity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The main hypothesis of this study is that transcranial magnetic neuromodulation can correct the symptoms of hypersensitivity and bladder pain. The investigators assume that under the influence of transcranial magnetic stimulation, both the subjective state of patients assessed by standardized questionnaires and the objective parameters assessed by invasive and non-invasive urodynamic studies will be improved. In this study, two protocols for magnetic stimulation of the supplementary motor area (SMA) will be compared with each other and with placebo. The investigators expect to determine the dependence of the therapeutic effect on the applied stimulation protocol.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04721210
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Transcranial magnetic stimulation
Trials testing the same drug.
- NCT07167940 — Rapid Acceleration Process for Intensive Treatment of PTSD in 5 Days · Phase 3 · not yet recruiting
- NCT07035119 — Transcranial Magnetic Stimulation for Chronic Scrotal Content Pain · Phase 1, PHASE2 · not yet recruiting
- NCT07369960 — Repetitive Transcranial Magnetic Stimulation Combined With Language Training for Language Disorders in Children With Glo · NA · recruiting
- NCT07085910 — Hebbian-Type Associative Stimulation in Stroke Rehabilitation · NA · not yet recruiting
- NCT06376734 — Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness · Phase 2 · recruiting
Other Joint-Stock Company North-West Center for Evidence-Based Medicine, Russian Federation trials
Trials by the same sponsor.
- NCT04807569 — The Effectiveness of Peripheral Magnetic Stimulation in Men With Lower Urinary Tract Symptoms · NA · unknown
- NCT04578899 — "The Effectiveness of Transvertebral Magnetic Neuromodulation in Patients With Detrusor Overactivity" · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04721210 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Joint-Stock Company North-West Center for Evidence-Based Medicine, Russian Federation
- Last refreshed: 19 March 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04721210.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing